Role of adipokines in the obesity-inflammation relationship: The effect of fat removal

Plastic and Reconstructive Surgery

Volumn 118, Issue 4, 2006, Pages 1048-1057

  Esposito, Katherine ^a   Giugliano, Giovanni ^a   Scuderi, Nicolò ^a   Giugliano, Dario ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BARIATRIC SURGERY; BIOLOGICAL ACTIVITY; BODY BUILD; BODY FAT; BODY FAT DISTRIBUTION; CARDIOVASCULAR RISK; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ESTHETIC SURGERY; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; LIPOSUCTION; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVERNUTRITION; PHYSICAL ACTIVITY; PLASTIC SURGERY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; WEIGHT REDUCTION;

ADIPONECTIN; ADIPOSE TISSUE; C-REACTIVE PROTEIN; CYTOKINES; HUMANS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; LIPECTOMY; OBESITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748773616     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.prs.0000232281.49432.ce     Document Type: Review

References (109)

1. Flegal, K. M., Carroll, M. D., Ogden, C. L., et al. Prevalence and trends in obesity among US adults, 1999-2000. J.A.M.A. 288: 1723, 2002.
2. Flegal, K. M., Carroll, M. D., Kuczmarski, R. J., and Johnson, C. L. Overweight and obesity in the United States: Prevalence and trends, 1960-1994. Int. J. Obes. Relat. Metab. Disord. 22: 39, 1998.
3. Serdula, M. K., Mokdad, A. H., Williamson, D. F., et al. Prevalence of attempting weight loss and strategies for controlling weight. J.A.M.A. 282: 1353, 1999.
4. National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity, and health risk. Arch. Intern. Med. 160:898, 2000.
5. World Health Organization. Obesity: Preventing and Managing the Global Epidemics. Geneva: World Health Organization, 1998.
6. National Heart Lung and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Obes. Res. 6 (Suppl. 2): 51S, 1998.
7. Troiano, R. P., Flegal, K. M., Kuczmarski, R. J., et al. Overweight prevalence and trends for children and adolescents: The National Health and Nutrition Examination Surveys, 1963 to 1991. Arch. Pediatr. Adolesc. Med. 149: 1085, 1995.
8. Trayhurn, P., and Beattie, J. H. Physiological role of adipose tissue: White adipose tissue as an endocrine and secretory organ. Proc. Nutr. Soc. 60: 329, 2001.
9. Ziccardi, P., Nappo, F., Giugliano, G., et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105: 804, 2002.
10. Lin, Y., Lee, H., Berg, A. H., et al. LPS activated TRL-4 receptor induces synthesis of the closely related receptor TRL-2 in adipocytes. J. Biol. Chem. 275: 1104, 2000.
11. Blake, G. J., and Ridker, P. M. Inflammatory biomarkers and cardiovascular risk prediction. J. Intern. Med. 252: 283, 2002.
12. Alexander, R. W. Inflammation and coronary artery disease. N. Engl. J. Med. 331: 468, 1994.
13. Ross, R. Atherosclerosis: An inflammatory disease. N. Engl. J. Med. 340: 115, 1999.
14. Libby, P., Ridker, P. M., and Maseri, A. Inflammation and atherosclerosis. Circulation 105: 1135, 2002.
15. Pickup, J. C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27: 813, 2004.
16. Ford, E. S. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 22: 1971, 1999.
17. Papanicolaou, D. A., Wilder, R. L., Manolagas, S. C., et al. The pathophysiologic roles of interleukin-6 in human disease. Ann. Intern. Med. 128: 127, 1998.
18. Bastard, J. P., Maachi, M., Van Nhieu, J. T., et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J. Clin. Endocrinol. Metab. 87: 2084, 2002.
19. Mohamed-Ali, V., Goodrick, S., Rawesh, A., et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J. Clin. Endocrinol. Metab. 82: 4196, 1997.
20. Fried, S. K., Bunkin, D. A., and Greenberg, A. S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab. 83: 847, 1998.
21. Fernández-Real, J. M., Vayreda, M., Richart, C., et al. Circulating interleukin 6 levels, blood pressure and insulin sensitivity in apparently healthy men and women. J. Clin. Endocrinol. Metab. 86: 1154, 2001.
22. Kern, P. A., Ranganathan, S., Li, C., et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. 280: E745, 2001.
23. Bastard, J. P., Jardel, C., Bruckert, E., et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J. Clin. Endocrinol. Metab. 85: 3338, 2000.
24. Makin, T., Noguchi, Y., Yoshikawa, T., et al. Circulating interleukin 6 concentrations and insulin resistance in patients with cancer. Br. J. Surg. 85: 1658, 1998.
25. Vozarova, B., Weyer, C., Hanson, K., et al. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes. Res. 9: 414, 2001.
26. Pradhan, A. D., Manson, J. E., Rifai, N., et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. J.A.M.A. 286: 327, 2001.
27. Ridker, P. M., Rifai, N., Stampfer, M. J., et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101: 1767, 2000.
28. Tsigos, C., Papanicolaou, D. A., Kyrou, I., et al. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J. Clin. Endocrinol. Metab. 82: 4167, 1997.
29. Southern, C., Schulster, D., and Green, I. C. Inhibition of insulin secretion from rat islets of Langerhans by interleukin-6. Biochem. J. 272: 243, 1990.
30. Sandler, S., Bendtzen, K., Eizirik, D., et al. Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro. Endocrinology 126: 1288, 1990.
31. Senn, J. J., Klover, P. J., Nowak, I. A., et al. Suppressor of cytokine signaling-3 (SOCS-3): A potential mediator of interleukin-6 dependent insulin resistance in hepatocytes. J. Biol. Chem. 278: 13740, 2003.
32. Boden, G., and Shulman, G. I. Free fatty acids in obesity and type 2 diabetes: Defining their role in the development of insulin resistance and β-cell dysfunction. Eur. J. Clin. Invest. 32 (Suppl. 3): 14, 2002.
33. Fasshauer, M., Kralisch, S., Klier, M., et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 301: 1045, 2003.
34. Steensberg, A., Fischer, C. P., Sacchetti, M., et al. Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. J. Physiol. 548: 631, 2003.
35. Yki-Järvinen, H., Sammalkorpi, K., Koivisto, V. A., et al. Severity, duration, and mechanisms of insulin resistance during acute infections. J. Clin. Endocrinol. Metab. 69: 317, 1989.
36. Rus, H. G., Vlaicu, R., and Niculescu, F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 127: 263, 1996.
37. Bhagat, K., and Balance, P. Inflammatory cytokines impair endothelium dependent dilatation in human veins in vivo. Circulation 96: 3042, 1997.
38. Harris, T. B., Ferrucci, L., Tracy, R. P., et al. Mortality risk associated with elevated interleukin-6 and C-reactive protein in old age. Am. J. Med. 196: 506, 1999.
39. Biasucci, L. M., Vitelli, A., and Liuzzo, G.. Elevated levels of IL-6 in unstable angina. Circulation 94: 874, 1996.
40. Biasucci, L. M., Liuzzo, G., Fantuzzi, G., et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 99: 2079, 1999.
41. Hotamisligil, G. S., and Spiegelman, B. M. Tumor necrosis factor: A key component of the obesity-diabetes link. Diabetes 43: 1271, 1994.
42. Ofei, F., Hurel, S., Newkirk, J., et al. Effects of an engineered human anti-TNF- antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45: 881, 1996.
43. Beutler, B., and Cerami, A. The biology of cachectin/TNF: A primary mediator of the host response. Annu. Rev. Immunol. 7: 625, 1989.
44. Bruun, J. M., Lihn, A. S., Verdich, C., et al. Regulation of adiponectin by adipose tissue-derived cytokines: In vivo and in vitro investigations in humans. Am. J. Physiol. 285: E527, 2003.
45. Greenberg, A. S., and McDaniel, M. L. Identifying the links between obesity, insulin resistance and β-cell function: Potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur. J. Clin. Invest. 32 (Suppl. 3): 24, 2002.
46. Hotamisligil, G. S., Arner, P., Atkinson, R. L., et al. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes 46: 451, 1977.
47. Fernández-Real, J. M., Broch, M., Ricart, W., et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes 47: 1757, 1998.
48. Straczkowski, M., Kowalska, I., Stepien, A., et al. Increased plasma-soluble tumor necrosis factor-receptor 2 level in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes Care 25: 1824, 2002.
49. Dzienis-Straczkowska, S., Straczkowski, M., Szelachowska, M., et al. Soluble TNF receptors in young obese subjects with normal and impaired glucose tolerance. Diabetes Care 26: 875, 2003.
50. Lyon, C. J., Law, R. E., and Hsueh, V. A. Minireview: Adiposity, inflammation, and atherogenesis. Endocrinology 144: 2195, 2003.
51. Kahaleh, M. B., and Fan, P. S. Effect of cytokines on the production of endothelin by endothelial cells. Clin. Exp. Rheumatol. 15: 163, 1997.
52. Brasier, A. R., Li, J., and Wimbish, K. A. Tumor necrosis factor activates angiotensinogen gene expression by the Rel A transactivator. Hypertension 27: 1009, 1996.
53. Zinman, B., Hanley, A. J. G., Harris, S. B., et al. Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 84: 272, 1999.
54. Dörffel, Y., Lätsch, C., Stuhlmüller, B., et al. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 34: 113, 1999.
55. Rask-Madsen, C., Domínguez, H., Ihlemann, N., et al. Tumor necrosis factor-alpha inhibits insulin's stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans. Circulation 108: 1815, 2003.
56. Bullo, M., Garcia-Lorda, P., Megias, I., et al. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes. Res. 11: 525, 2003.
57. Hu, E., Liang, P., and Spiegelman, B. M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem. 271: 10697, 1996.
58. Statnick, M. A., Beavers, L. S., Conner, L. J., et al. Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int. J. Exp. Diabetes Res. 1: 81, 2000.
59. Yang, W. S., Lee, W. J., Funahashi, T., et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J. Clin. Endocrinol. Metab. 86: 3815, 2001.
60. Arita, Y., Kihara, S., Ouchi, N., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257: 79, 1999.
61. Weyer, C., Funahashi, T., Tanaka, S., et al. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 86: 1930, 2001.
62. Matsubara, M., Maruoka, S., and Katayose, S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J. Clin. Endocrinol. Metab. 87: 2764, 2002.
63. Hotta, K., Funahashi, T., Arita, Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 20: 1595, 2000.
64. Lindsay, R. S., Funahashi, T., Hanson, R. L., et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360: 57, 2002.
65. Spranger, J., Kroke, A., and Mohlig, M. Adiponectin and protection against type 2 diabetes mellitus. Lancet 361: 226, 2003.
66. Yamauchi, T., Kamon, J., Waki, H., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7: 941, 2001.
67. Fruebis, J., Tsao, T. S., Javorschi, S., et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. U.S.A. 98: 2005, 2001.
68. Yamauchi, T., Kamon, J., Minokoshi, Y., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8: 1288, 2002.
69. Wu, X., Motoshima, H., Mahadev, K., et al. Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes 52: 1355, 2003.
70. Scherer, P. E., Williams, S., Fogliano, M., et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 270: 26746, 1995.
71. Kubota, N., Terauchi, Y., Yamauchi, T., et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem. 277: 25863, 2002.
72. Kumada, M., Kihara, S., Sumitsuji, S., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler. Thromb. Vasc. Biol. 23: 85, 2003.
73. Yokota, T., Oritani, K., Takahashi, I., et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96: 1723, 2000.
74. Kappes, A., and Loffler, G. Influences of ionomycin, dibutyrylcyclic AMP and tumor necrosis factor-alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Horm. Metab. Res. 32: 548, 2000.
75. Halleux, C. M., Takahash, M., Delporte, M. L., et al. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem. Biophys. Res. Commun. 288: 1102, 2001.
76. Esposito, K., Pontillo, A., Di Palo, C., et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: A randomized trial. J.A.M.A. 289: 1799, 2003.
77. Castell, J. V., Gomez-Lechon, M. J., David, M., et al. Acute-phase response of human hepatocytes: Regulation of acute-phase protein synthesis by interleukin-6. Hepatology 12: 1179, 1990.
78. Tracy, R. P., Psaty, B. M., Macy, E., et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler. Thromb. Vasc. Biol. 17: 2167, 1997.
79. Yudkin, J. S., Stehouwer, C. D. A., Emeis, J. J., et al. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction. Arterioscler. Thromb. Vasc. Biol. 19: 972, 1999.
80. Festa, A., D'Agostino, R., Jr., Howard, G., et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102: 42, 2000.
81. Han, T. S., Sattar, N., Williams, K., et al. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25: 2016, 2002.
82. Ridker, P. M., Stampfer, M. J., and Rifai, N. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. J.A.M.A. 285: 2481, 2001.
83. Ridker, P. M., Hennekens, C. H., Buring, J. E., et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342: 836, 2000.
84. Pasceri, V., Willerson, J. T., and Yeh, E. T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102: 2165, 2000.
85. Szmitko, P. E., Wang, C.-H., Weisel, R. D., et al. New markers of inflammation and endothelial cell activation. Circulation 108: 1917, 2003.
86. van Exel, E., Gussekloo, J., de Craen, A. J., et al. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: The Leiden 85-Plus Study. Diabetes 51: 1088, 2002.
87. Esposito, K., Giugliano, D., Nappo, F., et al. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus: Campanian Postprandial Hyperglycemia Study Group. Circulation 110: 214, 2004.
88. Gunnett, C. A., Heistad D. D. Faraci, F. M. Interleukin-10 protects nitric oxide-dependent relaxation during diabetes: Role of superoxide. Diabetes 51: 1931, 2002.
89. Mallat, Z., Heymes, C., Ohan, J., et al. Expression of interleukin-10 in advanced human atherosclerotic plaques: Relation to inducible nitric oxide synthase expression and cell death. Arterioscler. Thromb. Vasc. Biol. 19: 611, 1999.
90. Heeschen, C., Dimmeler, S., Hamm, C. W., et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 107: 2109, 2003.
91. Kopelman, P. G. Obesity as a medical problem. Nature 404: 635, 2000.
92. Abate, N., Garg, A., Peshock, R. M., et al. Relationships of generalized and regional adiposity to insulin sensitivity in men. J. Clin. Invest. 96: 88, 1995.
93. Uusitupa, M., Lindi, V., Louheranta, A., et al. Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study. Diabetes 52: 2532, 2003.
94. Stevens, V. J., Obarzanek, E., Cook, N. R., et al. Long-term weight loss and changes in blood pressure: Results of the Trials of Hypertension Prevention, phase II. Ann. Intern. Med. 134: 1, 2001.
95. Matarasso, A., and Hutchinson, O. H. Z. Liposuction. J.A.M.A. 285: 266, 2001.
96. Samdal, F., Birkeland, K. I., Ose, L., et al. Effect of large-volume liposuction on sex hormones and glucose and lipid metabolism in females. Aesthetic Plast. Surg. 19: 131, 1995.
97. Lambert, E. V., Hudson, D. A., Bloch, C. E., et al. Metabolic response to localized surgical fat removal in nonobese women. Aesthetic Plast. Surg. 15: 105, 1991.
98. Hardy, K. J., Gill, G. V., and Bryson, J. R. Severe insulin-induced lipohypertrophy successfully treated by liposuction. Diabetes Care 16: 929, 1993.
99. Berntorp, E., Berntorp, K., Brorson, H., et al. Liposuction in Dercum's disease: Impact on haemostatic factors associated with cardiovascular disease and insulin sensitivity. J. Intern. Med. 243: 197, 1998.
100. Giese, S. Y., Bulan, E. J., Commons, G. W., et al. Improvements in cardiovascular risk profile with large-volume liposuction: A pilot study. Plast. Reconstr. Surg. 108: 510, 2001.
101. Gonzalez-Ortiz, M., Robles-Cervantes, J. A., Cardenas-Camarena, L., et al. The effects of surgically removing subcutaneous fat on the metabolic profile and insulin sensitivity in obese women after large-volume liposuction treatment. Horm. Metab. Res. 34: 446, 2002.
102. Klein, S., Fontana, L., Young, V. L., et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N. Engl. J. Med. 350: 2549, 2004.
103. Giugliano, G., Nicoletti, G., Grella, E., et al. Effect of liposuction on insulin resistance and vascular inflammatory markers in obese women. Br. J. Plast. Surg. 57: 190, 2004.
104. Esposito, K., Giugliano, G., and Giugliano, D. Metabolic effects of liposuction: Yes or no? N. Engl. J. Med. 351: 1354, 2004.
105. Matarasso, A., Kim, R. W., and Kral, J. G. The impact of liposuction on body fat. Plast. Reconstr. Surg. 102: 1686, 1998.
106. DeFronzo, R. A., Tobin, J. D., and Andres, R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am. J. Physiol. 237: E214, 1979.
107. Matthews, D. R., Hosker, J. P., Rudenski, A. S., et al. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412, 1985.
108. Gabriely, I., Ma, X. H., Yang, X. M., et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: An adipokine-mediated process? Diabetes 51: 2951, 2002.
109. Rohrich, R. J. Obesity in America: An increasing challenge for plastic surgeons. Plast. Reconstr. Surg. 114: 1889, 2004.